Vascular Invasion and Lymph Node Metastasis Mediate the Effect of CA242 on Prognosis in Hilar Cholangiocarcinoma Patients After Radical Resection

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Dec 29

PMID 36578939

Authors

Gang Heng

Benqi Huang

Yanbing Shen

Dan Wang

Zhen Lan

Yuxuan Yao

Jianxin Zhang

Jiankun Jia

Chengcheng Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Carbohydrate antigen 242 has been clinically used as a diagnostic biomarker for pancreatic cancer. However, the prognostic role of CA242 in hilar cholangiocarcinoma (HCCA) has not been identified. Also, it remains unclear to what extents the vascular invasion and lymph node metastasis mediate the effect of serum CA242 on prognosis.

Objective: This study aimed to investigate whether vascular invasion and lymph node metastasis mediate the relationship between CA242 levels and clinical prognosis in HCCA patients after radical resection.

Methods: Data of 234 HCCA patients who accepted radical resection from March 2008 to December 2014 were analyzed. Vascular invasion and lymph node metastasis were assessed by postoperative pathological examinations. Mediation analysis was performed to study the potential causal relationship between CA242 and overall survival (OS) and relapse-free survival (RFS). Survival analysis was performed using the Kaplan-Meier method.

Results: Among 234 HCCA patients, 104 patients (44.4%) with normal CA242 levels (≤ 20 IU/ml) had significantly better OS (p=0.004) and RFS (p=0.001) than those 130 patients (55.6%) with elevated CA242 levels (>20 IU/ml). The logistic analysis showed that elevated CA242 was an independent risk factor for vascular invasion (p=0.006) and lymph nodes metastasis (p=0.040). The causal mediation analysis indicated that the vascular invasion (p=0.012 for OS; p=0.036 for RFS) and lymph nodes metastasis (p=0.024 for OS; p=0.014 for RFS) played significant roles in mediating the effect of serum CA242 on OS and RFS.

Conclusion: Serum elevated CA242 could be a novel marker for prognosis prediction in HCCA patients. Vascular invasion and lymph node metastasis mediated the relationship between CA242 and clinical prognosis.

Citing Articles

An overview of extrahepatic cholangiocarcinoma: from here to where?.

Yang Y, Zhang X Front Oncol. 2023; 13:1171098.

PMID: 37197436 PMC: 10183586. DOI: 10.3389/fonc.2023.1171098.

References

Park H, Lee J, Choi J, Lee M, Kim H, Han J . Preoperative evaluation of bile duct cancer: MRI combined with MR cholangiopancreatography versus MDCT with direct cholangiography. AJR Am J Roentgenol. 2008; 190(2):396-405. DOI: 10.2214/AJR.07.2310. View

Mansour J, Aloia T, Crane C, Heimbach J, Nagino M, Vauthey J . Hilar cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015; 17(8):691-9. PMC: 4527854. DOI: 10.1111/hpb.12450. View

Nilsson O, Johansson C, Glimelius B, Persson B, Norgaard-Pedersen B, Andren-Sandberg A . Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9. Br J Cancer. 1992; 65(2):215-21. PMC: 1977720. DOI: 10.1038/bjc.1992.44. View

Cai W, Lin J, He G, Wang H, Lu J, Yang G . Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma. Int J Clin Exp Pathol. 2015; 7(11):7890-8. PMC: 4270533. View

Haglund C, Lindgren J, Roberts P, Kuusela P, Nordling S . Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9. Br J Cancer. 1989; 60(6):845-51. PMC: 2247259. DOI: 10.1038/bjc.1989.377. View

Li X, Guo X, Li H, Lin H, Sun Y . Serum carbohydrate antigen 242 expression exerts crucial function in the diagnosis of pancreatic cancer. Tumour Biol. 2014; 35(6):5281-6. DOI: 10.1007/s13277-014-1687-5. View

Lee J, Lee J, Park Y, Lee W, Kwon J, Song K . Prognostic Predictability of American Joint Committee on Cancer 8th Staging System for Perihilar Cholangiocarcinoma: Limited Improvement Compared with the 7th Staging System. Cancer Res Treat. 2020; 52(3):886-895. PMC: 7373861. DOI: 10.4143/crt.2020.023. View

Gaspersz M, Buettner S, van Vugt J, De Jonge J, Polak W, Doukas M . Evaluation of the New American Joint Committee on Cancer Staging Manual 8th Edition for Perihilar Cholangiocarcinoma. J Gastrointest Surg. 2019; 24(7):1612-1618. PMC: 7359130. DOI: 10.1007/s11605-019-04127-x. View

Lu J, Li B, Li F, Ye H, Xiong X, Cheng N . Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma involving the hepatic hilus versus hilar cholangiocarcinoma after curative-intent resection: Should they be recognized as perihilar cholangiocarcinoma or differentiated?. Eur J Surg Oncol. 2019; 45(11):2173-2179. DOI: 10.1016/j.ejso.2019.06.014. View

10.

Xu Z, Ou Y, Dai H, Wan K, Bie P, Chen Z . Elevated preoperative CA125 levels predicts poor prognosis of hilar cholangiocarcinoma receiving radical surgery. Clin Res Hepatol Gastroenterol. 2021; 45(6):101695. DOI: 10.1016/j.clinre.2021.101695. View

11.

Anderson B, Doyle M . Surgical Considerations of Hilar Cholangiocarcinoma. Surg Oncol Clin N Am. 2019; 28(4):601-617. DOI: 10.1016/j.soc.2019.06.003. View

12.

She W, Cheung T, Ma K, Tsang S, Dai W, Chan A . Defining the optimal bilirubin level before hepatectomy for hilar cholangiocarcinoma. BMC Cancer. 2020; 20(1):914. PMC: 7513475. DOI: 10.1186/s12885-020-07385-0. View

13.

Tennant P, Murray E, Arnold K, Berrie L, Fox M, Gadd S . Use of directed acyclic graphs (DAGs) to identify confounders in applied health research: review and recommendations. Int J Epidemiol. 2020; 50(2):620-632. PMC: 8128477. DOI: 10.1093/ije/dyaa213. View

14.

Lee H, Herbert R, McAuley J . Mediation Analysis. JAMA. 2019; 321(7):697-698. DOI: 10.1001/jama.2018.21973. View

15.

Calapkulu M, Sencar M, Ozturk Unsal I, Sakiz D, Duger H, Ozbek M . Tumor Volume Can Be Used as a Parameter Indicating the Severity of Disease in Parathyroid Cancer. Endocr Pract. 2021; 27(7):706-709. DOI: 10.1016/j.eprac.2021.01.006. View

16.

Greenland S, Pearl J, Robins J . Causal diagrams for epidemiologic research. Epidemiology. 1999; 10(1):37-48. View

17.

Loosen S, Roderburg C, Kauertz K, Koch A, Vucur M, Schneider A . CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma. Sci Rep. 2017; 7(1):16975. PMC: 5717041. DOI: 10.1038/s41598-017-17175-7. View

18.

Li R, Chen T, Hu J, Guo D, Zhang X, Deng D . Tumor volume of resectable adenocarcinoma of the esophagogastric junction at multidetector CT: association with regional lymph node metastasis and N stage. Radiology. 2013; 269(1):130-8. DOI: 10.1148/radiol.13122269. View

19.

Cillo U, Fondevila C, Donadon M, Gringeri E, Mocchegiani F, Schlitt H . Surgery for cholangiocarcinoma. Liver Int. 2019; 39 Suppl 1:143-155. PMC: 6563077. DOI: 10.1111/liv.14089. View

20.

Fabris L, Alvaro D . The prognosis of perihilar cholangiocarcinoma after radical treatments. Hepatology. 2012; 56(3):800-2. DOI: 10.1002/hep.25808. View